Skip to main content
. 2022 Feb 21;12(2):340. doi: 10.3390/biom12020340

Figure 5.

Figure 5

Efficacy. (A) Clinical response in SCI patients: 229/687 patients improved their SCI grade, resulting in a proportion of 0.35 (95% CI: 0.25–0.46). (B) Comparison of clinical improvement in SCI patients between treatment and control group: the proportion in the experimental group was remarkably higher (0.35 (95% CI: 0.27–0.44)) than in the control group (0.04 (95% CI: 0.01–0.22)). The calculated risk ratio was 3.89 (95% CI: 1.14–13.23) and p = 0.030.